Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced MelanomaGlobeNewsWire • 05/26/22
Iovance Biotherapeutics, Inc. (IOVA) CEO Dr. Fred Vogt on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 05/05/22
Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual MeetingGlobeNewsWire • 04/27/22
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022GlobeNewsWire • 04/26/22
Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewsWire • 04/25/22
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in MelanomaGlobeNewsWire • 04/05/22
Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant UpsideSeeking Alpha • 03/25/22
Iovance Biotherapeutics' Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)GlobeNewsWire • 03/15/22
Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual MeetingGlobeNewsWire • 03/08/22
Iovance Biotherapeutics' (IOVA) CEO Fred Vogt on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate UpdatesGlobeNewsWire • 02/24/22
Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022GlobeNewsWire • 02/11/22
Are These 7 of the Worst-Performing Stocks of 2021 Ready to Skyrocket This Year?The Motley Fool • 01/22/22
Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®GlobeNewsWire • 01/07/22
Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022GlobeNewsWire • 01/06/22